

Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration

Tania Jain,¹ Hua-Ling Tsai,² Hany Elmariah,³ Pankit Vachhani,⁴ Theodoros Karantanos,¹ Sarah A. Wall,⁵ Lukasz P. Gondek,¹ Asad Bashey,⁶ Alla Keyzner,⁷ Roni Tamari,⁸ Michael R. Grunwald,⁹ Sameem Abedin,¹⁰ Kalyan V. G. Nadiminti,¹¹ Madiha Iqbal,¹² Aaron T. Gerds,¹³ Auro Viswabandya,¹⁴ Shannon R. McCurdy,¹⁵ Monzr M. Al Malki,¹⁶ Ravi Varadhan,² Haris Ali,¹⁶ Vikas Gupta,¹⁴ Richard J. Jones¹ and Salman Otoukesh¹⁶

¹Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; ²Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; ³Department of Bone Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; ⁴Division of Hematology and Oncology, O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL, USA; ⁵Division of Hematology, The Ohio State University - James Comprehensive Cancer Center, Columbus, OH, USA; ⁶Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA, USA; ⁷The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁸Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical College, New York, NY, USA; ⁹Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; ¹⁰Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; ¹¹Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; ¹²Department of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA; ¹³Department of Hematology and Medical Oncology, Cleveland, OH, USA; ¹⁴Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; ¹⁵University of Pennsylvania, Philadelphia, PA, USA and ¹⁶Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA

Correspondence: T. Jain
tjain2@jhmi.edu

Received: April 25, 2023.

Accepted: June 29, 2023.

Early view: July 6, 2023.

<https://doi.org/10.3324/haematol.2023.283426>

©2023 Ferrata Storti Foundation

Published under a CC BY-NC license



SUPPLEMENTARY LEGEND:

Supplementary Table 1: Mutation frequency by sex of the patient

Supplementary Table 2: Details of conditioning regimens by conditioning intensity

Supplementary Table 3: Summary of HCT outcomes

Supplementary Figure 1: Association of age at HCT and intensity of conditioning regimen

Supplementary Table 1: Mutation frequency by sex of the patient

	Women (n=34)	Men (n=56)	P-value
Total number of mutations, median (range)	3 (0-5)	4 (0-7)	0.015
High-risk NGS:			0.19
No	15 (44%)	17 (30%)	
Yes	19 (56%)	39 (70%)	
ERS mutation			0.79
No	24 (71%)	38 (68%)	
Yes	10 (29%)	18 (32%)	

Supplementary Table 2: Details of conditioning regimens by conditioning intensity

Myeloablative conditioning (n=22/120, 18%)	Fludarabine TBI (1200cGy)	9
	Fludarabine Busulfan Thiotepa	4
	Fludarabine Melphalan Thiotepa	3
	Busulfan Cyclophosphamide	2
	Busulfan Fludarabine	1
	Busulfan Fludarabine Cyclophosphamide	1
	Fludarabine Cyclophosphamide TBI (1050 cGy)	1
	Fludarabine Melphalan TBI1200	1
Reduced-intensity conditioning (n=44/120, 37%)	Fludarabine Melphalan TBI (200 cGy)	15
	Fludarabine Cyclophosphamide TBI (400 cGy)	14
	Busulfan Fludarabine	6
	Busulfan Fludarabine TBI (200cGy)	4
	Fludarabine Melphalan	2
	Fludarabine Busulfan Thiotepa	2
	Fludarabine Melphalan Thiotepa	1
Non-myeloablative conditioning (n=54/120, 45%)	Fludarabine Cyclophosphamide TBI (200 cGy)	52
	Fludarabine Cyclophosphamide TBI (300 cGy)	2

Supplementary Table 3: Summary of HCT outcomes (N=120)

Outcomes		N (%) or median (range) or Cumulative incidence (95%CI)
Number of patients achieving ANC engraftment		111 (92.5%)
Median time to ANC engraftment in days (n=111)		18 (IQ range, 16-22)
Number of patients achieving platelet engraftment		103 (85.8%)
Median time to platelet engraftment in days (n=103)		31 (IQ range, 22.5 – 41)
Graft failure		7 (5.8%)
Cumulative incidence of NRM:	1 year 3 years	20% (13-28%) 25% (17-34%)
Cumulative incidence of relapse:	1 year 3 years	20% (13-27%) 27% (18-36%)
Cumulative incidence of grade 2-4 acute GVHD:	Day +100 1 year	28% (20-37%) 35% (27-44%)
Cumulative incidence of grade 3-4 acute GVHD:	Day +100 1 year	6% (2-10%) 12% (6-18%)
Cumulative incidence of chronic GVHD:	1 year 3 years	24% (16-32%) 33% (24-42%)
Cumulative incidence of chronic GVHD requiring systemic immunosuppression:	1 year 3 years	12% (6-17%) 14% (7-20%)
PFS:	1 year 3 years	60% (51-69%) 48% (39-59%)
OS:	1 year 3 years	70% (62-79%) 56% (47-67%)
CMV reactivation requiring intervention		35 (29.2%)
Time to CMV reactivation (n=35)		46 (27 – 203) days

Supplementary Figure 1: Association of age at HCT and intensity of conditioning regimen

